PART 1: The Role of NGS in Myeloid Leukemia

Myeloid malignancies are complex clonal diseases arising in hematopoietic stem or progenitor cells. These heterogenous disorders comprise many different subtypes such as myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and acute myeloid leukemia (AML). There is a growing need for molecular profiling of these blood and bone marrow disorders to provide better definition… Read article →

BRCA Testing – Making Treatment Decisions Today and Planning for the Future

The ubiquity of the pink ribbon campaign, the prevalence of precision medicine as a recurring theme in every scientific and medical journal, and the very fact that BRCA has entered the lexicon of society – globally – suggests that breast cancer testing is standard. Indeed, something that has been part of everyday life for some… Read article →

NGS is helping oncologists make informed treatment decisions

For decades, tissue-conserving surgery coupled with chemotherapy (either preceding or following surgery, depending on the size of the tumor(s)) followed by radiation has been the standard of care for the majority of cancers. Over the past fifteen years, chemoradiotherapy (concurrently dosing a patient with chemotherapy and radiation) has improved the overall survival rates especially for… Read article →

EHA 2018

Stop by the QIAGEN booth #1160 at the 23rd EHA Congress from June 14-17, 2018 at Stockholm, where we will be featuring our latest Sample to Insight solutions, from trusted molecular detection to clinical decision support.

2018 ASCO Annual Meeting

We’re excited to attend the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Learn more.

AMP Europe 2018

Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.  

Key findings from a product launch survey in the pharma industry

Today, patients want to know more about new treatment options as they come to market, and be more engaged in their treatment decisions, receive more personalized healthcare and, ultimately, feel confident that they’re receiving the best treatment. This means that launching new products in this evolving environment will require launch teams from pharmaceutical companies to… Read article →

Liquid biopsy to detect tumor DNA: The possibilities

An article published on WBUR’s CommonHealth blog opens a window into liquid biopsy, also referred to as blood biopsy, in its current and future state. The article discusses how this rapidly-evolving technology has the potential to transform the way we detect and treat cancer. The technology of liquid biopsy is rapidly evolving, but still has… Read article →

QIAGEN receives FDA clearance for first-ever JAK2 test for use in diagnosis of additional myeloproliferative neoplasms

Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the… Read article →

QIAGEN at NGS Bioinformatics Challenge in Germany

QIAGEN had the pleasure of taking part in an NGS Bioinformatics Challenge run by the German Society for Pathology on the 9th and 10th of November in Halle, Germany. Three commercial organizations were supplied with vcf files from twelve samples sequenced using Illumina MiSeq™ Systems and the IonTorrent platform at Erlangen, Cologne Berlin. The identity… Read article →

Webinar: A clinical view on PITX2 DNA methylation in high-risk breast cancer

A webinar program for oncologists and pathologists Thursday, Feb. 22, 2018 at 1:00 p.m. CET Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that… Read article →

PITX2: A novel biomarker to support breast cancer therapy selection

PITX2 DNA methylation status is a clinically relevant biomarker to predict survival in a variety of cancers, including breast cancer, and is a predictive biomarker for treatment response in high- risk breast cancer patients. Applying PITX2 methylation as a predictive biomarker can help avoid use of chemotherapy in patients that would receive  little or no… Read article →

Multi-center study shows QIAGEN’s ipsogen JAK2 MutaQuant Kit is robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation

A network study of multiple laboratories finds the ipsogen JAK2 MutaQuant Kit to be robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation. This study sets the basis for the standardization of molecular techniques for JAK2 V617F determination. The JAK2 V617F mutation is an important diagnostic biomarker for Philadelphia (Ph)- negative myeloproliferative… Read article →

QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data

Studies presented at AMP Global conference in Berlin reaffirm powerful analytical performance and ease of use for the world’s first complete Sample to Insight NGS solution Hilden, Germany, April 3, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced further validation of the GeneReader NGS System with the publication of five new… Read article →

QIAGEN launches first FDA-cleared JAK2 test for certain type of leukemia

New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →